Items where authors include "John, N."

Article

Chataway, J., Williams, T., Blackstone, J. et al. (135 more authors) (2025) Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, 406 (10512). pp. 1611-1624. ISSN 0140-6736

Abani, O., Abbas, A., Abbas, F. et al. (7724 more authors) (2025) Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Kalincik, T. orcid.org/0000-0003-3778-1376, Sharmin, S., Roos, I. orcid.org/0000-0003-0371-3666 et al. (46 more authors) (2025) Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis. Brain. awaf286. ISSN 0006-8950

De Angelis, F., Cameron, J.R., Eshaghi, A. et al. (14 more authors) (2025) Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 96 (7). pp. 647-654. ISSN 0022-3050

Abani, O., Abbas, A., Abbas, F. et al. (8041 more authors) (2025) Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. EClinicalMedicine, 81. 103080. ISSN 2589-5370

Blackstone, J., Williams, T., Nicholas, J.M. et al. (59 more authors) (2024) Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. BMJ Open, 14 (9). e086414. ISSN 2044-6055

John, N., Li, Y., De Angelis, F. et al. (49 more authors) (2024) Brain reserve and physical disability in secondary progressive multiple sclerosis. BMJ Neurology Open, 6 (2). e000670. ISSN 2632-6140

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Williams, T., John, N., Calvi, A. et al. (18 more authors) (2023) Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross‐sectional analysis from the MS‐STAT2 randomized controlled trial. European Journal of Neurology, 30 (9). pp. 2769-2780. ISSN 1351-5101

Kalincik, T., Sharmin, S., Roos, I. et al. (150 more authors) (2023) Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurology, 80 (7). pp. 702-713. ISSN 2168-6149

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736